TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Lindberg Life-Science AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
1
|
0
|
0 |
| Financial expenses |
6
|
0
|
20 |
| Earnings before taxes |
-19
|
1
|
-27 |
| EBITDA |
-11
|
-3
|
-4 |
| Total assets |
42
|
20
|
20 |
| Current assets |
16
|
1
|
4 |
| Current liabilities |
2
|
1
|
8 |
| Equity capital |
40
|
19
|
11 |
| - share capital |
5
|
4
|
5 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
95.2%
|
95.0%
|
55.0% |
| Turnover per employee | |||
| Profit as a percentage of turnover | -1900% | ||
| Return on assets (ROA) |
-31.0%
|
5.0%
|
-35.0% |
| Current ratio |
800%
|
100%
|
50.0% |
| Return on equity (ROE) |
-47.5%
|
5.3%
|
-245.5% |
| Change turnover |
1
|
0
|
-12 |
| Change turnover % | -100% | ||
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.